|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin add to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, muhicenter, randomized, double- blind, placebo-controlled, parallel-group study 显示文摘 | Rosenstock J Brazg R Andryuk PJ | 2006 | Clin Ther2006，28，10： | 1 |
| 2 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel- group study显示文摘 | Rosenstock J Brazg R Andryuk P J | 2006 | Clinical Ther2006，28，10： | 1 |
| 3 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added lo ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study 显示文摘 | Rosenstock J Brazg R Andryuk P J | 2006 | Clin Ther2006，28，10： | 1 |
| 4 | Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycemic control and beta-cell function in patients with type 2 diabetes 显示文摘 | Brazg R Xu L Dalla Man C | 2007 | Diabetes Obes Metab2007，9，2： | 1 |
| 5 | Effi-cacy and safety of the dipeptidyl peptidase-4 inhibitorsitagliptin added to ongoing pioglitazone therapy in patientswith type 2 diabetes : a 24-week, multicenter, randomized,double-blind,placebo-controlled,parallel-group study 显示文摘 | ROSENSTOCK J BRAZG R ANDRYUK P J | 2006 | Clin Ther2006，28，10： | 1 |
| 6 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes:a 24-week,multicenter,randomized,double-blind,placebo-controlled,parallel-group study显示文摘 | Rosenstock J Brazg R Andryuk PJ | 2006 | Clin Ther2006，28，10： | 1 |
| 7 | for the Sitagliptin Study 019Group Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sita- gliptin added to ongoing pioglitazone therapy in patients with type 2 dia- betes : a 24 - week, multicenter, randomized, double - blind, placebo - controlled, parallel - group study显示文摘 | Rosenstock J Brazg R Andryuk PJ | 2006 | Clin Ther2006，28，： | 1 |
| 8 | Susceptibility of small dense,lowdensity lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype,patternB显示文摘 | Chait A Brazg R L Tribble D L | 1993 | Am J Med1993，94，： | 1 |
| 9 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebocontrolled, parallel group study显示文摘 | Rosenstock J Brazg R Andryuk PI | 2006 | Clin Ther2006，28，10： | 1 |
| 10 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor Sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study 显示文摘 | ROSENSTOCK J BRAZG R ANDRYUK P J | 2006 | Clin Ther2006，28，10： | 1 |
| 11 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin add to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study 显示文摘 | Rosenstock J Brazg R Andryuk PJ | 2006 | Clin Ther2006，28，10： | 1 |
| 12 | Effect of adding MK- 0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin 显示文摘 | BRAZG R THOMAS K ZHAO P | 2005 | Diabetes2005，54，1： | 1 |
| 13 | Effext of adding MK-0431 to on-go- ing metforrnin therapy in type 2 diabetic patients who have inadequate glycemic control on mefformin 显示文摘 | Brazg R Thoma K Zhao PL | 2005 | Diabetes2005，54，： | 1 |
| 14 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing ploglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo controlled, parallel-group study显示文摘 | Rosenstock J Brazg R Andryuk PJ | 2006 | Clin Ther2006，28，： | 1 |
| 15 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes:a 24-week,multicenter,randomized,double-blind,placebo-controlled,parallel-group study显示文摘 | Rosenstock J Brazg R Andryuk PJ | 2006 | Clin Ther2006，28，10： | 1 |
| 16 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes:a 24-week,multicenter,randomized,double-blind,placebo-controlled,parallel-group study显示文摘 | Brazg R Andryuk PJ | 2006 | Clin Ther2006，28，1： | 1 |
| 17 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2diabetes:a 24-week,multicenter,randomized,doubleblind,placebo-controlled,parallel-group study显示文摘 | ROSENSTOCK J BRAZG R ANDRYUK PJ | 2006 | Clin Ther2006，28，10： | 1 |
| 18 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitragliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo controlled, parallel-group study显示文摘 | Rosenstock J Brazg R Andryuk PJ | 2006 | Clin Ther2006，10，： | 1 |
| 19 | Effect of addng MK- 0431 to ongoing metform in therapy in type 2 diabetic patents who have inadequate glycaemic control on metformin显示文摘 | Brazg R Thomas K Zhao P | 2005 | Diabetes2005，54，1： | 1 |
| 20 | Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes 显示文摘 | Brazg R Xu L Dalla Man C | 2007 | Diabetes Obes Metab2007，9，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员